Cellectisの発行済株式数
Cellectisの発行済株式数は何ですか。
Cellectisの発行済株式数は72.094Mです。
発行済株式数の定義は何ですか。
発行済株式数は、投資家によって承認、発行、購入され、保有されている法人または金融資産のすべての株式である。
Shares outstanding includes all stock held by investors including both common shares held by the public and restricted shares owned by the company's internal managements. Shares outstanding have rights and represent an ownership in the corporation by the person who holds the shares. They are distinguished from treasury shares, which are shares held by the corporation itself and have no exercisable rights. Shares outstanding plus treasury shares together amount to the number of issued shares.
Shares outstanding can be calculated as either basic or fully diluted. The basic count is the current number of shares. Dividend distributions and voting in the general meeting of shareholders are calculated according to this number. The fully diluted shares outstanding count, on the other hand, includes diluting securities, such as warrants, capital notes or convertibles. If the company has any diluting securities, this indicates the potential future increased number of shares outstanding. A company's market capitalization is calculated by multiplying the price of one of its shares by the total number outstanding shares a company has issued.
NASDAQのセクタHealth Careにおける発行済株式数の企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似の発行済株式数
- Shanghai MicroPort Endovascular MedTech Coの発行済株式数は71.978Mです。
- BlackRock Municipal Income Fund Incの発行済株式数は71.992Mです。
- Tripleの発行済株式数は71.996Mです。
- Satin Creditcare Networkの発行済株式数は72.020Mです。
- Global Net Leaseの発行済株式数は72.025Mです。
- Stockmann Oyj Abpの発行済株式数は72.049Mです。
- Cellectisの発行済株式数は72.094Mです。
- Cloud DXの発行済株式数は72.094Mです。
- Bioasis Technologiesの発行済株式数は72.144Mです。
- Urban Exposure Plcの発行済株式数は72.156Mです。
- Titan Internationalの発行済株式数は72.159Mです。
- BGR Systemsの発行済株式数は72.162Mです。
- BGR Systemsの発行済株式数は72.162Mです。